Current Diabetes Reports

, Volume 2, Issue 3, pp 269–273 | Cite as

Heart protection study: LDL lowering therapy and cardiovascular outcomes in patients with low cholesterol levels or diabetes

  • Mrinalini Kulkarni
  • Peter D. Reaven
Clinical Trials Report

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.Google Scholar
  2. 2.
    Kannel WB, Castelli WP, Gordon T, McNamara PM: Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study. Ann Intern Med 1971, 74:1–12.PubMedGoogle Scholar
  3. 3.
    Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major events: final report of the Pooling Project Research Group [no authors listed]. J Chronic Dis 1978, 31:201–306.Google Scholar
  4. 4.
    Goldbourt V, Holtzman E, Neufeld HN: Total and high-density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. BMJ 1985, 290:1239–1243.PubMedCrossRefGoogle Scholar
  5. 5.
    Sacks FM, Moye LA, Davis BR, et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 1998, 97:1446–1452.PubMedGoogle Scholar
  6. 6.
    Pedersen TR, Olsson AG, Faergeman O, et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453–1460.PubMedGoogle Scholar
  7. 7.
    Stamler J, Wentworth D, Neaton JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continous and graded? Findings in 356,222 primary screenees of the Muliple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823–2828.PubMedCrossRefGoogle Scholar
  8. 8.
    Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.PubMedCrossRefGoogle Scholar
  9. 9.
    Robins SJ, Collins D, Wittes JT: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585–1591.PubMedCrossRefGoogle Scholar
  10. 10.
    MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. MRC/BHF Heart Protection Study Collaborative group [no authors listed]. Eur Heart J 1999, 20:725–741.CrossRefGoogle Scholar
  11. 11.
    Armitage J, Collins R: Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials [editorial]. Heart 2000, 84:357–360.PubMedCrossRefGoogle Scholar
  12. 12.
    Omenn GS, Goodman GE, Thornquist M, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996, 334:1150–1155.PubMedCrossRefGoogle Scholar
  13. 13.
    Stephens NG, Parsons A, Schofield PM, et al.: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781–786.PubMedCrossRefGoogle Scholar
  14. 14.
    Boaz M, Smetana S, Weinstein T, et al.: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): a randomized placebo-controlled trial. Lancet 2000, 356:1213–1218.PubMedCrossRefGoogle Scholar
  15. 15.
    Cheung MC, Zhao XQ, Chait A, et al.: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001, 21:1320–1326.PubMedGoogle Scholar
  16. 16.
    Hayden J, Reaven PD: Cardiovascular disease in diabetes type 2: a potential role for novel cardiovascular risk factors. Curr Opin Lipidol 2000, 11:519–528.PubMedCrossRefGoogle Scholar
  17. 17.
    Steinberg D: Is there a potential role for vitamin E or other antioxidants in atherosclerosis? Curr Opin Lipidol 2000, 11:603–607.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2002

Authors and Affiliations

  • Mrinalini Kulkarni
  • Peter D. Reaven
    • 1
  1. 1.Department of Medicine (CS/111E)Carl T. Hayden VAMCPhoenixUSA

Personalised recommendations